MOTS-c contraindications: who should not use it, and why

Last updated 2026-07-24

Is MOTS-c actually contraindicated for anyone, medically speaking?

Contraindication is a specific word. It means a regulatory body or a clinical trial program looked at a drug, found a condition where the risk clearly outweighs benefit, and put that in writing on an approved label. MOTS-c has none of that. It is not an FDA-approved drug. Search Drugs@FDA, the agency's own database of approved drug products, and you will not find it ^[1]. No phase 3 trial. No package insert. No boxed warning. So when people ask about MOTS-c contraindications, what they are really asking is: given what we know about its biology, who should stay away from it? That's a fair question, and it deserves a real answer, but it's a different question than 'what does the label say,' because there is no label. Most of what we know comes from mouse studies, cell culture, and a handful of mechanistic papers published between 2015 and 2026. That is not nothing. It is also not a safety trial in humans. Keep that gap in mind through every section below.

Why is cancer history the biggest theoretical concern with MOTS-c?

MOTS-c's biology is fundamentally about cell survival and stress response, and that cuts both ways. A 2024 study in Advanced Science found MOTS-c suppressed ovarian cancer progression in a specific mechanism, by attenuating USP7-mediated LARS1 deubiquitination ^[2]. That sounds like good news, and in that specific cancer model, it was framed as protective. But a peptide that can suppress one cancer pathway by manipulating protein stability and stress signaling is a peptide that manipulates the same cellular machinery cancer cells sometimes hijack for their own survival. MOTS-c works partly through translocating to the nucleus and directly regulating gene expression under metabolic stress, a mechanism described in Cell Metabolism in 2018 ^[3] and reviewed further in BioEssays in 2019 ^[4]. Any molecule that reaches into the nucleus and changes transcription in response to stress is a molecule you want tested carefully in the specific cancer context before anyone with an active malignancy touches it. The honest position: the ovarian cancer finding is one study, in one cancer type, showing a protective association in that specific model. It is not a green light for people with cancer, and it is not evidence the opposite direction either. It is a reason to be cautious and specific, not a reason to be alarmist or reassuring. If you have active cancer, a history of cancer, or an undiagnosed mass, this is not a decision to make without an oncologist in the room.

Is MOTS-c safe during pregnancy or breastfeeding?

There is no human safety data on MOTS-c in pregnancy, full stop. The closest relevant study is a 2022 paper in Pharmacological Research showing MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus model ^[5]. That is an animal model of a pregnancy-specific metabolic condition, not a human safety study, and it does not tell us anything about fetal exposure, placental transfer, or developmental effects in people. Given zero human reproductive safety data, the standard and sensible approach is to treat MOTS-c the way you'd treat any unapproved peptide during pregnancy or lactation: don't use it. This isn't a hedge to sound cautious. It's the actual state of the evidence. Nobody has done the studies that would let you make an informed decision here, which means the decision defaults to no.

Can people with muscle or bone conditions safely use MOTS-c?

This is where the data is most interesting, and also most rodent-heavy. A 2021 study in the American Journal of Physiology found MOTS-c reduces myostatin and muscle atrophy signaling ^[6]. A 2024 paper in the same journal found MOTS-c attenuated immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration ^[7]. A 2022 study in Peptides showed MOTS-c promotes muscle differentiation in vitro, meaning in cell culture, not in a living animal or human ^[8]. And a 2024 iScience paper found MOTS-c modulates skeletal muscle function by directly binding and activating CK2, an enzyme involved in muscle signaling ^[9]. On bone, a 2023 review in Frontiers in Physiology covers MOTS-c's role in bone metabolism regulation ^[10], and a 2025 study in Free Radical Biology & Medicine found MOTS-c attenuated mitochondrial dysfunction, pyroptosis, and cartilage degradation in an osteoarthritis model through an Nrf2-dependent mechanism ^[11]. None of this is a contraindication. If anything, this is the strongest theoretical case for MOTS-c in musculoskeletal contexts. But 'strongest theoretical case' still means rodent models and cell culture, not human trials in people with sarcopenia or osteoarthritis. If you're exploring MOTS-c for muscle or joint reasons, read the mots-c dosage page before assuming a mouse dose translates to a human one, because it usually doesn't in any simple way.

Does MOTS-c interact with diabetes medication or affect blood sugar too much?

This is the single most-studied angle on MOTS-c, and it's worth taking seriously if you're on glucose-lowering medication. The foundational 2015 Cell Metabolism paper that put MOTS-c on the map found it promotes metabolic homeostasis and reduces obesity and insulin resistance in mice ^[12]. A 2023 Metabolites paper is literally titled 'MOTS-c Functionally Prevents Metabolic Disorders' ^[13], and a 2023 review in Diabetes & Metabolism Journal covers MOTS-c's relationship to diabetes and aging-related disease broadly ^[14]. More recent work has gotten specific: a 2025 paper in Experimental & Molecular Medicine found MOTS-c prevents pancreatic islet cell senescence to delay diabetes onset in a model ^[15]. A 2025 paper in Cardiovascular Drugs and Therapy asks bluntly whether MOTS-c is a 'magical molecule' for diabetic cardiomyopathy ^[16], which tells you the field is excited but still asking, not answering. If MOTS-c genuinely lowers insulin resistance and improves glucose handling the way the animal data suggests, then stacking it with insulin, sulfonylureas, or other glucose-lowering drugs is a real hypoglycemia risk worth discussing with whoever manages your diabetes care, even though no clinical trial has quantified that interaction in humans. This is exactly the kind of gap where 'we don't have the data yet' is the correct and complete answer, not a reason to guess.

Are there respiratory or lung conditions where MOTS-c should be avoided or used carefully?

MOTS-c shows up repeatedly in lung injury models, which is worth knowing if you have chronic respiratory disease and are curious about it. A 2025 Redox Biology study found MOTS-c attenuates lung ischemia-reperfusion injury through a MYH9-dependent mechanism involving nuclear translocation and antioxidant gene activation ^[17]. A 2023 paper in European Journal of Pharmacology found MOTS-c suppresses ferroptosis (a specific type of iron-dependent cell death) and reduces acute lung injury from myocardial ischemia reperfusion, via the PPARγ pathway ^[18]. A 2023 Mitochondrion paper describes MOTS-c as a potential anti-pulmonary fibrosis factor ^[19]. A 2025 study in International Immunopharmacology found it attenuates airway barrier dysfunction in an allergic asthma model by inhibiting epithelial cell death through the Nrf2 pathway ^[20]. And a 2025 American Journal of Respiratory Cell and Molecular Biology paper found MOTS-c promotes glycolysis through the AMPK-HIF-1α-PFKFB3 pathway to help with cardiopulmonary bypass-induced lung injury ^[21]. All six of these are animal or cell models of acute injury or specific disease states, not studies of MOTS-c given to people with COPD, asthma, or fibrosis as an ongoing supplement. There's no signal here that MOTS-c is dangerous for lung disease. There's also no human trial saying it's safe or effective for anyone's actual asthma or COPD. If you have a chronic respiratory condition and you're taking MOTS-c anyway, that's not covered by any of this literature, and it's worth flagging to your pulmonologist.

Does MOTS-c cause or worsen inflammation, and who should watch for that?

MOTS-c's core biology involves the Nrf2 antioxidant pathway and immune-adjacent signaling, which shows up across a surprising number of unrelated conditions. A 2024 study in Gut found MOTS-c has an antiviral role during hepatitis B infection through mitochondrial remodeling ^[22]. A 2024 paper in Theranostics found MOTS-c helps repair plasma membranes by facilitating TRIM72 translocation ^[23]. A 2025 Materials Today Bio paper describes MOTS-c-modified hydrogels enhancing stem cell activity in intervertebral disc degeneration ^[24]. None of these point to a contraindication. They point to a molecule with effects across immune, membrane-repair, and tissue-remodeling systems that nobody has mapped fully in humans. That breadth is exactly why 'exercise in a pill' is the wrong frame, addressed more below, and why anyone with an active autoimmune condition or on immunosuppressants should treat MOTS-c as an unknown, not a known-safe supplement.

Is 'MOTS-c mimics exercise' a real finding or a marketing claim?

It's a claim built on a real mechanistic overlap, stretched further than the data supports. MOTS-c is genuinely tied to exercise physiology: a 2021 review in Biochimica et Biophysica Acta covers mitochondrial-derived peptides and exercise broadly ^[25], and a 2022 Diabetes & Metabolism Journal paper specifically covers exercise, mitohormesis, and MOTS-c ^[26]. A 2025 Scientific Reports paper found MOTS-c 'mimics exercise' to fight diabetic liver fibrosis in a rodent model by targeting the Keap1-Nrf2-Smad2/3 pathway ^[27], and that paper's own title is the source of a lot of the 'exercise in a pill' language you see in marketing copy. Here's the honest read: MOTS-c is released during and after exercise in animal models, and some of its downstream effects overlap with what exercise does metabolically. That is genuinely interesting biology. It is not the same as showing that taking MOTS-c produces the cardiovascular, muscular, neurological, and psychological benefits of an actual workout in a human being. Nobody has run that trial. Exercise also does dozens of things (bone loading, cardiovascular conditioning, neuromuscular coordination, mood effects) that a single circulating peptide is unlikely to replicate. Treat 'exercise mimetic' as a hypothesis test scientists are excited about, not a finding you can bank on for yourself.

Is there any human clinical trial data on MOTS-c safety at all?

A 2023 review in Frontiers in Endocrinology calls MOTS-c 'a promising mitochondrial-derived peptide for therapeutic exploitation' ^[28], which is optimistic language, but read the paper itself and the promise is about mechanism and animal data, not completed human trials. A 2026 paper in Sports Medicine reviews the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance broadly, which is one of the closer things to a human-safety-context review in this space ^[29]. There is no published randomized controlled trial establishing a human safety profile, dose-response curve, or adverse event rate for MOTS-c. That's not a criticism of the researchers. Peptide drug development is slow and expensive, and MOTS-c is roughly a decade into its research life since the 2015 Cell Metabolism discovery paper ^[12]. It just means anyone using MOTS-c today, through a compounding pharmacy or otherwise, is operating well ahead of the safety data, not behind it.

What about a genuinely strange finding: could MOTS-c make aging worse in some contexts?

Yes, and this one gets buried under the enthusiasm. A 2018 paper in Rejuvenation Research is titled, plainly, 'Mitochondrial-Derived Peptides Exacerbate Senescence' ^[30]. This is a real, published, peer-reviewed finding that at least one mitochondrial-derived peptide context showed a senescence-promoting effect, the opposite direction of the anti-aging framing MOTS-c usually gets in supplement marketing. This doesn't mean MOTS-c definitely accelerates aging in some people. It means the biology is not uniformly 'younger and better' in every model tested, and a molecule this connected to cell stress, senescence, and mitochondrial signaling can plausibly cut in more than one direction depending on cell type, dose, and existing disease state. If a company tells you MOTS-c is unambiguously anti-aging with no caveats, that company is not being straight with you about the literature.

Is unregulated or compounded MOTS-c itself a contraindication risk?

Separate from the biology, there's a regulatory reality that matters more than most buyers realize. MOTS-c is not on the FDA's 503A bulk drug substances list ^[31] or the 503B bulk drug substances list ^[32], the two lists that define what compounding pharmacies can legally use under 21 U.S.C. § 353a ^[33]. FDA's own guidance on bulk drug substances used in compounding under Section 503A lays out this framework directly ^[34], and the agency maintains a running list of substances nominated for that use ^[35], a list MOTS-c has been nominated to but not added to as of this writing. What that means practically: any MOTS-c product you can buy is not an FDA-approved drug, and if it's sold as a compounded medication, it exists in a regulatory space the FDA has not formally endorsed for this specific peptide. That's a sourcing and purity risk layered on top of the biological unknowns already discussed. If you're going to use it anyway, the source matters as much as the molecule. Read mots-c side effects before deciding, and if you're evaluating vendors, mots-c peptide buy covers what separates a provider-reviewed source from an anonymous one. MOTS-c Co's own listings only surface options that have gone through provider review and route through a named fulfilling pharmacy partner, specifically because 'contraindications' for an unregulated peptide start with 'do you actually know what's in the vial.'

What should you actually do if you're considering MOTS-c and have a health condition?

Talk to a physician who knows your full history before starting, not after. That sounds obvious, but it's the single most protective step given how thin the human safety data is. Bring the specific studies relevant to your condition, not marketing copy, so the conversation is grounded in what's actually been shown. If you have active cancer, a strong family cancer history, are pregnant or breastfeeding, or are on insulin or other glucose-lowering medication, treat those as hard stop conditions until better human data exists, not soft cautions. If you're generally healthy and curious about the muscle, metabolic, or exercise-adjacent findings, understand you're an early adopter of a molecule with a strong rodent story and no completed human safety trial. Check mots-c peptide injection and a mots-c 10mg dosage calculator if you get that far, but don't let a dosing calculator substitute for the medical judgment a contraindication decision actually requires.

Frequently asked questions

Does MOTS-c have an FDA-approved contraindication label?

No. MOTS-c is not an FDA-approved drug and does not appear in the Drugs@FDA database of approved products. There is no official label, so there is no official contraindication list. Any contraindication guidance, including this article, is inferred from mechanistic and animal research, not from a regulatory review.

Can people with cancer take MOTS-c?

Not without oncology guidance. A 2024 Advanced Science study found MOTS-c suppressed ovarian cancer progression in a specific model, but MOTS-c also directly regulates nuclear gene expression under stress, the same kind of pathway cancer cells can hijack. One protective finding in one cancer type doesn't clear MOTS-c for general use in anyone with active or past malignancy.

Is MOTS-c safe during pregnancy?

There's no human pregnancy safety data at all. The only related study is a 2022 Pharmacological Research paper on MOTS-c in a gestational diabetes animal model, which says nothing about fetal safety. Given zero human reproductive data, the standard approach is to avoid MOTS-c during pregnancy and breastfeeding entirely.

Does MOTS-c interact with insulin or diabetes medication?

No human interaction study exists, but the risk is plausible. Multiple animal studies, including the original 2015 Cell Metabolism paper, show MOTS-c lowers insulin resistance and improves glucose handling. Combined with insulin or sulfonylureas, that raises a theoretical hypoglycemia risk that anyone on glucose-lowering medication should discuss with their prescriber first.

Is MOTS-c actually 'exercise in a pill'?

That's marketing shorthand for a narrower finding. MOTS-c is released during exercise and overlaps with some exercise-linked metabolic pathways, as covered in a 2022 Diabetes & Metabolism Journal review and a 2025 Scientific Reports paper on diabetic liver fibrosis. It hasn't been shown to replicate exercise's cardiovascular, muscular, and neurological benefits in humans.

Can MOTS-c make aging or senescence worse?

Possibly, in some contexts. A 2018 Rejuvenation Research paper titled 'Mitochondrial-Derived Peptides Exacerbate Senescence' found a senescence-promoting effect for this peptide class, the opposite of the usual anti-aging framing. It's a reminder the biology isn't uniformly protective across every cell type and condition.

Is MOTS-c legal to buy and use in the United States?

MOTS-c isn't FDA-approved and isn't on the FDA's 503A or 503B bulk drug substance lists that govern legal compounding. It has been nominated for consideration but isn't formally added. Products sold as MOTS-c exist in a gray regulatory zone, which is a separate risk from the biological unknowns.

Does MOTS-c affect muscle wasting or atrophy conditions?

Animal data is encouraging but not human-proven. A 2021 study found MOTS-c reduces myostatin and muscle atrophy signaling, and a 2024 paper found it reduced immobilization-induced muscle atrophy in an animal model. These are rodent findings; no human trial has tested MOTS-c for sarcopenia or clinical muscle wasting.

Should people with lung disease avoid MOTS-c?

There's no evidence it's dangerous, but there's also no human trial in people with asthma, COPD, or pulmonary fibrosis. MOTS-c shows protective effects in several animal lung injury models (ischemia-reperfusion, fibrosis, allergic asthma), but none of that translates to a safety claim for someone using it alongside an existing chronic lung condition.

Are there drug interactions documented for MOTS-c?

None have been formally studied in humans. The main plausible interaction, based on mechanism rather than trial data, is with glucose-lowering diabetes medications, given MOTS-c's insulin-sensitizing effects in animal models. No published human pharmacokinetic or interaction study exists for MOTS-c with any drug class.

Is MOTS-c safe for children or adolescents?

There's no data on this population at all. All published MOTS-c research uses adult animal models, adult cell lines, or discusses adult human disease contexts theoretically. Without any pediatric safety or dosing data, MOTS-c use in children or adolescents isn't supported by anything in the current literature.

What's the biggest gap in MOTS-c safety research right now?

The complete absence of a published human clinical trial establishing dose-response, adverse event rates, or a safety profile. A 2026 Sports Medicine review and a 2023 Frontiers in Endocrinology review both describe MOTS-c as promising for therapeutic development, but promising for future trials is not the same as proven safe for current use.

Sources

1. FDA, Drugs@FDA database: MOTS-c is not listed as an FDA-approved drug product
2. Advanced Science, 2024 (PMID 39321430): MOTS-c suppressed ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination in a study model
3. Cell Metabolism, 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate gene expression in response to metabolic stress
4. BioEssays, 2019 (PMID 31378979): MOTS-c functions as a mitochondrial-encoded regulator of nuclear gene expression
5. Pharmacological Research, 2022 (PMID 34798268): MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus animal model
6. American Journal of Physiology: Endocrinology and Metabolism, 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling in a study model
7. American Journal of Physiology: Endocrinology and Metabolism, 2024 (PMID 38170165): MOTS-c attenuated immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
8. Peptides, 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
9. iScience, 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
10. Frontiers in Physiology, 2023 (PMID 37200834): MOTS-c has a role in the regulation of bone metabolism
11. Free Radical Biology & Medicine, 2025 (PMID 41043625): MOTS-c attenuated mitochondrial dysfunction, pyroptosis, and cartilage degradation in an osteoarthritis model via an Nrf2-dependent mechanism
12. Cell Metabolism, 2015 (PMID 25738459): MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in a mouse model
13. Metabolites, 2023 (PMID 36677050): MOTS-c functionally prevents metabolic disorders in study models
14. Diabetes & Metabolism Journal, 2023 (PMID 36824008): MOTS-c is reviewed in the context of diabetes and aging-related disease
15. Experimental & Molecular Medicine, 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes onset in a study model
16. Cardiovascular Drugs and Therapy, 2025 (PMID 40172798): MOTS-c is discussed as a candidate molecule for diabetic cardiomyopathy, with the question posed rather than settled
17. Redox Biology, 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via a MYH9-dependent mechanism
18. European Journal of Pharmacology, 2023 (PMID 37290680): MOTS-c suppresses ferroptosis and alleviates acute lung injury via PPARγ signaling
19. Mitochondrion, 2023 (PMID 37307934): MOTS-c is described as a potential anti-pulmonary fibrosis factor
20. International Immunopharmacology, 2025 (PMID 40472776): MOTS-c attenuates airway barrier dysfunction in allergic asthma by inhibiting epithelial apoptosis via the Nrf2 pathway
21. American Journal of Respiratory Cell and Molecular Biology, 2025 (PMID 40035775): MOTS-c promotes glycolysis via the AMPK-HIF-1α-PFKFB3 pathway to reduce cardiopulmonary bypass-induced lung injury
22. Gut, 2024 (PMID 37788894): MOTS-c has an antiviral role during hepatitis B infection through mitochondrial remodeling
23. Theranostics, 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation
24. Materials Today Bio, 2025 (PMID 40510834): MOTS-c-modified hydrogels enhance stem cell activity in a model of intervertebral disc degeneration
25. Biochimica et Biophysica Acta General Subjects, 2021 (PMID 34520826): Mitochondrial-derived peptides including MOTS-c are linked to exercise physiology
26. Diabetes & Metabolism Journal, 2022 (PMID 35656563): MOTS-c is discussed in the context of exercise and mitohormesis
27. Scientific Reports, 2025 (PMID 40425777): MOTS-c mimics exercise effects to combat diabetic liver fibrosis by targeting the Keap1-Nrf2-Smad2/3 pathway in a study model
28. Frontiers in Endocrinology, 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide for therapeutic exploitation, based on mechanistic research
29. Sports Medicine, 2026 (PMID 41966639): Review covers safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance
30. Rejuvenation Research, 2018 (PMID 30058454): Mitochondrial-derived peptides can exacerbate cellular senescence in a study model
31. eCFR, 21 CFR 216.23: Defines the 503A bulk drug substances list governing legal compounding ingredients, which does not include MOTS-c
32. eCFR, 21 CFR 216.24: Defines the 503B bulk drug substances list governing outsourcing facility compounding ingredients, which does not include MOTS-c
33. Cornell Law School, 21 U.S.C. 353a: Establishes the statutory framework under which pharmacy compounding of bulk substances is permitted
34. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA guidance describing which bulk substances may legally be used in 503A compounding
35. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): MOTS-c has been nominated for consideration on the FDA bulk drug substance list but has not been added to it